Jazz Pharmaceuticals earnings were $482.2M for the trailing 12 months ending Mar 31, 2025, with 48.9% growth year over year. The latest JAZZ earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$92.5M, down 148.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, JAZZ reported annual earnings of $560.1M, with 35% growth.
JAZZ past earnings growth
How has JAZZ's earnings growth performed historically?
Jazz Pharmaceuticals Earnings Reports & History FAQ
What were Jazz Pharmaceuticals's earnings last quarter?
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 2025 earnings per share (EPS) of -$1.52, up 560.87% year over year. Total JAZZ earnings for the quarter were -$92.54 million. In the same quarter last year, Jazz Pharmaceuticals's earnings per share (EPS) was -$0.23.
Is Jazz Pharmaceuticals profitable or losing money?
As of the last Jazz Pharmaceuticals earnings report, Jazz Pharmaceuticals is currently profitable. Jazz Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $482.20 million, a 45.77% increase year over year.
What was JAZZ's earnings growth in the past year?
As of Jazz Pharmaceuticals's earnings date in Q2 2025, Jazz Pharmaceuticals's earnings has grown 48.95% year over year. This is 37.42 percentage points higher than the US Biotechnology industry earnings growth rate of 11.53%. JAZZ earnings in the past year totalled $482.20 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.